ALLERGY

Authored by
mohammad looti

November 7, 2025

ALLERGY

Primary Disciplinary Field(s): Immunology, Medicine, Pathology

1. Core Definition

An **allergy** is a chronic condition characterized by an exaggerated or inappropriate immunological response to generally harmless environmental substances known as **allergens**. This immune overreaction results in tissue inflammation and pathological symptoms ranging from mild irritation to life-threatening anaphylaxis. Unlike normal immunity, which defends against true pathogens, allergic reactions occur due to a misidentification of non-pathogenic foreign molecules (such as pollen, dust mite proteins, or specific foods) as threats, prompting a defensive cascade. This phenomenon is classified primarily as a Type I (immediate) hypersensitivity reaction in the Gell and Coombs classification system, though other forms of hypersensitivity may contribute to specific allergic syndromes.

The essence of the allergic response involves two distinct phases: sensitization and elicitation. During the initial **sensitization phase**, the immune system encounters the allergen and begins producing large quantities of a specific class of antibodies, typically Immunoglobulin E (**IgE**). These IgE molecules then bind to high-affinity receptors on the surface of mast cells located in mucosal tissues and basophils circulating in the blood. This binding prepares the immune system for a rapid response upon subsequent exposure.

The **elicitation phase** occurs upon re-exposure to the same allergen. The allergen cross-links the IgE antibodies already bound to the mast cell surface. This cross-linking triggers the rapid degranulation of the mast cell, releasing potent chemical mediators stored in its granules. The most critical mediator released is **histamine**, alongside leukotrienes, prostaglandins, and various cytokines, which collectively lead to the characteristic acute symptoms of allergy, including vasodilation, increased vascular permeability, smooth muscle contraction, and localized tissue swelling.

2. Etymology and Historical Development

The concept of an abnormal immune response, though observed clinically for centuries, was formally recognized and named in the early 20th century. The term **allergy** was coined in 1906 by the Austrian pediatrician Clemens von Pirquet. Pirquet observed that some of his patients reacted adversely to foreign substances, such as injected serum or vaccines, upon secondary exposure, developing symptoms like rash or fever that were different from the expected immunological outcome. He derived the term from the Greek words *allos* (meaning 'other' or 'altered') and *ergon* (meaning 'reaction' or 'work'), intending it to mean an 'altered reaction' of the body.

Pirquet's initial definition encompassed both protective immunity and hypersensitivity reactions, viewing both as deviations from the norm. However, over time, the term narrowed specifically to describe detrimental hypersensitivity responses. Early research focused heavily on identifying the specific agents--the allergens--responsible for conditions like hay fever and asthma. The discovery of IgE in 1967 by Japanese and Swedish researchers, particularly K. Ishizaka and T. Ishizaka, provided the crucial missing link, finally clarifying the primary humoral mechanism underlying Type I hypersensitivity and shifting the understanding of allergies from a general constitutional predisposition to a specific, measurable immunological pathway.

The subsequent development of laboratory techniques allowed scientists to measure IgE levels and identify specific allergens with unprecedented precision. This foundational work paved the way for modern allergology, confirming the distinction between IgE-mediated reactions (true allergies) and non-IgE mediated intolerances or sensitivities, a distinction critical for accurate diagnosis and effective management today.

3. Immunological Mechanism: The Hypersensitivity Pathway

The allergic pathway is fundamentally driven by a skewed T-helper cell response. When an individual is genetically predisposed (atopic) and encounters an allergen, antigen-presenting cells (APCs) process the allergen and present its epitopes to T lymphocytes. In allergic individuals, this process favors the differentiation of naive T cells into T helper 2 (**Th2**) cells, rather than the regulatory Th1 cells associated with standard cellular immunity. This Th2 dominance is central to the development of allergy.

Th2 cells are crucial orchestrators of the humoral response specific to allergy. They release a specific repertoire of signaling molecules, notably the cytokines Interleukin-4 (IL-4), Interleukin-5 (IL-9), and Interleukin-13 (IL-13). IL-4 and IL-13 are instrumental in initiating the process of **isotype switching** in B lymphocytes, guiding them to switch from producing general antibodies (like IgM or IgG) to producing IgE antibodies specifically targeted against the encountered allergen. IL-5, meanwhile, is heavily involved in the activation, growth, and survival of eosinophils, another cell type highly characteristic of chronic allergic inflammation.

Once the allergen-specific IgE antibodies are produced, they circulate in the bloodstream before binding firmly to the Fc epsilon Receptor I (**FcεRI**), which is densely expressed on the membranes of mast cells and basophils. These cells are essentially armed sentinels, loaded with pre-formed inflammatory mediators. Upon subsequent exposure, the allergen acts as a bridge, cross-linking multiple adjacent IgE molecules on the cell surface. This instantaneous signaling cascade within the mast cell triggers two simultaneous reactions: the rapid release of pre-formed mediators (degranulation) and the synthesis of newly generated lipid mediators (e.g., leukotrienes and prostaglandins) and cytokines, leading rapidly to the clinical symptoms of allergy.

4. Key Components and Mediators

The acute pathology of allergy is dictated by a cocktail of powerful chemical mediators released upon mast cell and basophil activation. Understanding these components is essential for targeted pharmacological treatment.

The single most well-known mediator is **histamine**, a vasoactive amine that accounts for many immediate symptoms. Histamine binds to H1 receptors, causing arteriolar dilation, which leads to localized redness and heat, and increasing the permeability of post-capillary venules, resulting in fluid leakage into the tissues (swelling and edema). In the respiratory tract, histamine causes the contraction of bronchial smooth muscles (leading to bronchospasm and difficulty breathing) and stimulates mucus secretion. The rapid onset of these effects makes histamine the primary target for over-the-counter and prescription antihistamine medications.

Other crucial mediators include **leukotrienes** (specifically LTB4, LTC4, LTD4, and LTE4), which are derived from the metabolism of arachidonic acid. Leukotrienes are significantly more potent than histamine in causing smooth muscle contraction, particularly in the bronchi, making them highly relevant in allergic asthma. Prostaglandin D2 (**PGD2**) is also released and contributes to vasodilation and bronchoconstriction. Furthermore, activated mast cells release various enzymes (e.g., tryptase) and chemotactic factors that recruit other inflammatory cells, such as **eosinophils**. Eosinophils, while recruited later, sustain chronic allergic inflammation by releasing toxic granular proteins and perpetuating tissue damage in conditions like eczema and chronic asthma.

5. Clinical Manifestations and Classification

Allergies present a wide spectrum of clinical syndromes depending on the route of allergen exposure and the target organ system. These manifestations are generally categorized based on the affected area:

The respiratory system is commonly affected, leading to conditions such as **Allergic Rhinitis** (hay fever), where symptoms include sneezing, nasal congestion, and pruritus, often triggered by inhaled allergens like pollen or mold spores. When the lower respiratory tract is affected, **Allergic Asthma** results, characterized by reversible airway obstruction, chronic inflammation, and bronchial hyperresponsiveness. The skin is also a frequent site, presenting as **Urticaria** (hives), marked by raised, intensely itchy wheals, or **Atopic Dermatitis** (eczema), a chronic condition involving dry, inflamed, and intensely itchy skin lesions, particularly common in children.

Gastrointestinal allergies, primarily to foods like peanuts, milk, or shellfish, manifest as vomiting, diarrhea, and abdominal pain. The most severe manifestation across all systems is **anaphylaxis**, a systemic, life-threatening reaction marked by the rapid onset of severe symptoms, including widespread vasodilation (leading to a dangerous drop in blood pressure), severe bronchospasm,

and circulatory collapse. Anaphylaxis requires immediate treatment with epinephrine (adrenaline) to stabilize the patient.

Respiratory Allergies: Allergic Rhinitis, Allergic Asthma.
Cutaneous Allergies: Urticaria (Hives), Angioedema, Atopic Dermatitis.
Systemic Reactions: Anaphylaxis (most severe, potentially fatal).
Gastrointestinal Allergies: Eosinophilic Esophagitis, Food protein-induced enterocolitis syndrome (FPIES).

6. Diagnosis and Testing Methods

Accurate diagnosis is crucial for effective allergy management and relies heavily on identifying the specific allergen responsible for the patient's symptoms. The diagnostic process typically involves a combination of clinical history taking and specific immunological testing.

The gold standard for identifying IgE-mediated immediate hypersensitivity is the **Skin Prick Test (SPT)**. This procedure involves placing small amounts of standardized allergen extracts onto the skin, typically the forearm or back, and then lightly pricking the skin surface to allow the allergen to penetrate the epidermis. A positive reaction, indicated by the development of a wheal (swelling) and flare (redness) within 15 to 20 minutes, confirms the presence of allergen-specific IgE bound to cutaneous mast cells. While highly sensitive, the SPT requires careful interpretation as false positives can occur, and certain medications (like antihistamines) must be discontinued prior to the test.

When skin testing is contraindicated (e.g., due to widespread skin disease or patient inability to discontinue antihistamines), *in vitro* blood tests are utilized. The **Specific IgE Antibody Test**, often referred to as a Radioallergosorbent Test (RAST) or modern ImmunoCAP assay, measures the quantity of circulating IgE antibodies specific to a given allergen in the patient's serum. Higher levels of specific IgE correlate strongly with clinical allergy. For food allergies, diagnosis often involves combining these tests with an **Elimination Diet** followed by a strictly monitored **Oral Food Challenge (OFC)**, which is considered the definitive diagnostic tool, though it carries a risk of inducing a severe reaction.

7. Treatment and Management Strategies

Management of allergies follows a three-pronged approach: avoidance, pharmacotherapy, and immunotherapy. The most fundamental strategy involves **allergen avoidance**, minimizing exposure to known triggers (e.g., using HEPA filters for dust mites, or strictly eliminating specific foods). While effective, complete avoidance is often impractical or impossible.

Pharmacotherapy focuses on symptomatic relief and inflammation control. **Antihistamines** block

the effects of released histamine at its receptors, effectively reducing pruritus, sneezing, and rhinorrhea. For moderate to severe chronic inflammation, particularly in asthma and rhinitis, **Corticosteroids** (often delivered topically or by inhalation) are essential, as they suppress the underlying inflammatory cascade, reducing the number of inflammatory cells and decreasing mucosal reactivity. Other drugs include leukotriene receptor antagonists (useful in asthma) and mast cell stabilizers (e.g., cromolyn sodium).

The only available treatment that modifies the underlying immune response and offers long-term remission is **Allergen Immunotherapy (AIT)**, often called allergy shots or sublingual tablets. AIT involves administering gradually increasing doses of the specific allergen extract over several years. This process aims to reprogram the immune system, shifting the balance from a destructive Th2 response to a regulatory Th1 response, leading to the production of blocking antibodies (IgG) and a decrease in IgE levels and mast cell reactivity. AIT is highly effective for insect venom, pollen, and dust mite allergies, significantly reducing symptom severity and medication reliance.

8. Significance and Impact

Allergies represent a significant global public health burden. The prevalence of allergic diseases, particularly asthma, allergic rhinitis, and atopic dermatitis, has risen dramatically in industrialized nations over the past few decades, a trend often linked to the **Hygiene Hypothesis**. This hypothesis suggests that reduced exposure to microbes and infectious agents early in life leads to an unbalanced immune system development, favoring the Th2 allergic pathway over the protective Th1 pathway.

The impact of allergies extends beyond immediate symptoms, severely affecting the patient's quality of life. Chronic conditions like asthma and severe rhinitis lead to sleep disturbances, poor performance in school or work, and substantial psychological distress. Furthermore, the economic cost associated with allergies is immense, encompassing expenditures on diagnosis, medication, emergency room visits for severe reactions (anaphylaxis), and loss of productivity. For instance, food allergies necessitate constant vigilance, imposing significant psychosocial stress on families and restricting dietary and social freedoms.

Understanding and managing allergies is therefore crucial not only for individual patient care but also for addressing broader epidemiological trends. As environmental factors and genetic predispositions interact, the medical community continues to research the complex interplay that leads the body to generate an irregular or incorrect immune reaction to select antigens, provoking the excretion of histamine and leading to swelling and various other ailments.

Further Reading

Asthma and Allergy Foundation of America (AAFA)

National Institute of Allergy and Infectious Diseases (NIAID)
Clemens von Pirquet
Immunological Mechanisms of Hypersensitivity (Gell and Coombs Classification)